Intrinsically active nanobody-modified polymeric micelles for tumor-targeted combination therapy
- 1 November 2012
- journal article
- research article
- Published by Elsevier BV in Biomaterials
- Vol. 34 (4), 1255-1260
- https://doi.org/10.1016/j.biomaterials.2012.09.064
Abstract
No abstract availableKeywords
Funding Information
- European Commission
- NWO-CW/STW (790.36.110, 10154)
- ZonMw Pre Seed (93611001)
- GAČR (P-301/11/0325)
- DFG (LA-2937/1-1)
This publication has 27 references indexed in Scilit:
- Nanomedicine(s) under the MicroscopeMolecular Pharmaceutics, 2011
- Delivering nanomedicine to solid tumorsNature Reviews Clinical Oncology, 2010
- Downregulation of EGFR by a novel multivalent nanobody-liposome platformJournal of Controlled Release, 2010
- Mechanism of active targeting in solid tumors with transferrin-containing gold nanoparticlesProceedings of the National Academy of Sciences, 2009
- Combination therapy: Opportunities and challenges for polymer–drug conjugates as anticancer nanomedicinesAdvanced Drug Delivery Reviews, 2009
- Nanoparticle therapeutics: an emerging treatment modality for cancerNature Reviews Drug Discovery, 2008
- Tumour-targeted nanomedicines: principles and practiceBritish Journal of Cancer, 2008
- Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imagingProceedings of the National Academy of Sciences, 2007
- Physicochemical Characterization of Degradable Thermosensitive Polymeric MicellesLangmuir, 2004
- HPMA-hydrogels result in prolonged delivery of anticancer drugs and are a promising tool for the treatment of sensitive and multidrug resistant leukaemiaEuropean Journal Of Cancer, 2002